Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients

Cancer Science

Volumn 100, Issue 11, 2009, Pages 2167-2174

  Niu, Yamei ^a,c   Terasaki, Yasunobu ^a   Komatsu, Nobukazu ^a   Noguchi, Masanori ^b   Shichijo, Shigeki ^a   Itoh, Kyogo ^a  

^a Department of Immunology and Immunotherapy ^*  (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLSERYLLEUCYLASPARTYLSERYLASPARTYLPROLYLTRYPTOPHYLVALINE; ARGINYLLEUCYLGLUTAMYLTRYPTOPHYLCYSTEINYLSERYLVALYLISOLEUCINE; ASPARAGINYLTYROSYLSERYLVALYLARGINYLTYROSYLARGINYLPROLYGLYCYLLEUCINE; ASPARAGINYLVALYLLEUCYLHISTIDINYLPHENYLALANYLPHENYLALANYLASPARAGINYLALANYLPROLYLLEUCINE; ASPARTYLLEUCYLLEUCYLSERYLHISTIDINYLALANYLPHENYLALANYLPHENYLALANYLALANINE; ASPARTYLTYROSYLLEUCYLARGINYLSERYLVALYLLEUCYLGLUTAMYLASPARTYLPHENYLALANINE; ASPARTYLTYROSYLSERYLALANYLARGINYLTRYPTOPHYLASPARAGINYLGLUTAMYLISOLEUCINE; ASPARTYLVALYLTRYPTOPHYLSERYLPHENYLALANYLGLYCYLISOLEUCYLLEUCYLLEUCINE; CANCER VACCINE; CD8 ANTIGEN; HISTIDINYLTYROSYLARGINYLLYSLTRYPTOPHYLISOLEUCYLLYSYLASPARTYLTHREONYLISOLEUCINE; HISTIDINYLTYROSYLTHREONYLASPARAGINYLALANYLSERYLASPARTYLGLYCYLLEUCINE; HLA A ANTIGEN; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA A26 ANTIGEN; HLA A3 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA C ANTIGEN; LEUCYLLEUCYLALANYLALANYLGLUTAMYLALANYLPROLYLARGINYLLEUCINE; LEUCYLTYROSYLCYSTEINYLGLUTAMYLSERYLVALYLHISTIDINYLASPARAGINYLPHENYLALANINE; LYSYLLEUCYLLYSYLHISTIDINYLTYROSYLGLYCYLPROLYLGLYCYLTRYPTOPHYLVALINE; LYSYLLEUCYLVALYLGLUTAMYLARGINYLLEUCYLGLYCYLALANYLALANINE; MONOCLONAL ANTIBODY; PEPTIDE VACCINE; TYROSYLLEUCYLLEUCYLPROLYLARGINYLARGINYLGLYCYLPROLYLARGINYLLEUCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALYLTYROSYLASPARTYLTYROSYLASPARAGINYLCYSTEINYLHISTIDINYLVALYLASPARTYLLEUCINE;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER PATIENT; CELL ISOLATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG RESEARCH; HUMAN; HUMAN CELL; JAPANESE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMANS; MICE; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 71049158010     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01298.x     Document Type: Article

References (21)

1. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T. Allele and Haplotype Frequencies for HLA and Complement Loci in Various Ethnic Groups 1992, Oxford, UK, Oxford Scientific Publications
2. Niu Y, Komatsu N, Komohara Y. A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients infected with HCV with various HLA class IA alleles. J Med Virol 2009, 81:1232-1240.
3. Mohamed ER, Naito M, Terasaki Y. Capability of SART3109-118 peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles. Int J Oncol 2009, 34:529-36.
4. Matsueda S, Takedatsu H, Yao A. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clin Cancer Res 2005, 11:6933-43.
5. Pinol-Roma S, Swanson MS, Gall JG, Dreyfuss G. A novel heterogeneous nuclear RNP protein with a unique distribution on nascent transcripts. J Cell Biol 1989, 109:2575-87.
6. Verissimo F, Jordan P. WNK kinases, a novel protein kinase subfamily in multi-cellular organisms. Oncogene 2001, 20:5562-9.
7. Ito M, Shichijo S, Tsuda N. Molecular basis of T cell-mediated recognition of pancreatic cancer cells. Cancer Res 2001, 61:2038-46.
8. Mine T, Sato Y, Noguchi M. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 2004, 10:929-37.
9. Takedatsu H, Shichijo S, Azuma K, Sata M, Itoh K. Detection of a set of peptide vaccine candidates for use in HLA-A31+ epithelial cancer patients. Int J Oncol 2004, 24:337-47.
10. Takedatsu H, Shichijo S, Katagiri K, Sawamizu H, Sata M, Itoh K. Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients. Clin Cancer Res 2004, 10:1112-20.
11. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-9.
12. Neumann-Haefelin C, Killinger T, Timm J. Absence of viral escape within a frequently recognized HLA-A26-restricted CD8+ T-cell epitope targeting the functionally constrained hepatitis C virus NS5A/5B cleavage site. J Gen Virol 2007, 88:1986-91.
13. Yang D, Nakao M, Shichijo S. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999, 59:4056-63.
14. Murayama K, Kobayashi T, Imaizumi T. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J Immunother 2000, 23:511-8.
15. del Guercio MF, Sidney J, Hermanson G. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 1995, 154:685-93.
16. Sidney J, Grey HM, Southwood S. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum Immunol 1996, 45:79-93.
17. Torikai H, Akatsuka Y, Miyauchi H. The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206. Bone Marrow Transplant 2007, 40:165-74.
18. Terasaki Y, Shichijo S, Niu Y. An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles. Cancer Immunol Immunother 2009, DOI
19. Takiguchi M, Matsuda T, Tomiyama H, Miwa K. Analysis of three HLA-A*3303 binding peptide anchors using an HLA-A*3303 stabilization assay. Tissue Antigens 2000, 55:296-302.
20. Nakao M, Yamana H, Imai Y. HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res 1995, 55:4248-52.
21. Kawakami Y, Rosenberg SA. T-cell recognition of self peptides as tumor rejection antigens. Immunol Res 1996, 15:179-90.